Literature DB >> 25246138

Shenqi Fuzheng Injection for advanced gastric cancer: a systematic review of randomized controlled trials.

Jiang Li1, Jian-Cheng Wang, Bin Ma, Wei Gao, Peng Chen, Rao Sun, Ke-Hu Yang.   

Abstract

OBJECTIVE: To evaluate the effectiveness of Shenqi Fuzheng Injection (, SFI) combined with chemotherapy for advanced gastric cancer.
METHODS: Randomized controlled trials (RCTs) from 10 databases were searched for this meta-analysis till December 31, 2012 without language restriction. Grey literature and potential unpublished literature was also searched. The key search terms were "chemotherapy", "Shenqi Fuzheng Injection" and "advanced gastric cancer". Criteria were built to select these clinical trials, in which SFI combined with chemotherapy was compared with chemotherapy alone for advanced gastric cancer. The methodological quality of each RCT was assessed using the Cochrane risk of bias tool. RevMan 5.1 software was applied for data analyses.
RESULTS: Thirteen RCTs involving 860 patients met the selection criteria (all articles were from Chinese databases). The meta-analysis showed positive results for the use of SFI combined with chemotherapy according to quality of life in terms of the scores when compared with chemotherapy alone. Positive results were also obtained for the combination treatment, in terms of complete remission and partial remission efficacy rate, body weight and decreased adverse events including nausea and vomiting at grade 3-4, oral mucositis at grade 1-2, leucopenia at grade 3-4, and myelo-suppression at grade 1-2.
CONCLUSIONS: This systematic review found encouraging albeit limited evidence for SFI combined with chemotherapy. However, to obtain stronger evidence without the drawbacks of trial design and the quality of studies, we recommend comparative effectiveness researches to test the effectiveness of combination treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25246138     DOI: 10.1007/s11655-014-1768-8

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  23 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

3.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Authors:  D Moher; B Pham; A Jones; D J Cook; A R Jadad; M Moher; P Tugwell; T P Klassen
Journal:  Lancet       Date:  1998-08-22       Impact factor: 79.321

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 5.  Gastric cancer: global pattern of the disease and an overview of environmental risk factors.

Authors:  D Forman; V J Burley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

6.  Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer.

Authors:  Jennifer M Yeh; Chin Hur; Karen M Kuntz; Majid Ezzati; Sue J Goldie
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

7.  Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review.

Authors:  C X Pan; R S Morrison; J Ness; A Fugh-Berman; R M Leipzig
Journal:  J Pain Symptom Manage       Date:  2000-11       Impact factor: 3.612

8.  Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.

Authors:  P J Hollen; R J Gralla; M G Kris; C Cox; C P Belani; S M Grunberg; J Crawford; J A Neidhart
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

9.  Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Authors:  A Roy; D Cunningham; R Hawkins; H Sörbye; A Adenis; J-R Barcelo; G Lopez-Vivanco; G Adler; J-L Canon; F Lofts; C Castanon; E Fonseca; O Rixe; J Aparicio; J Cassinello; M Nicolson; M Mousseau; A Schalhorn; L D'Hondt; J Kerger; D K Hossfeld; C Garcia Giron; R Rodriguez; P Schoffski; J-L Misset
Journal:  Br J Cancer       Date:  2012-07-05       Impact factor: 7.640

10.  Validation of the functional assessment of cancer therapy-gastric module for the Chinese population.

Authors:  Hui Jun Zhou; Jimmy B Y So; Wei Peng Yong; Nan Luo; Feng Zhu; Nasheen Naidoo; Shu Chuen Li; Khay Guan Yeoh
Journal:  Health Qual Life Outcomes       Date:  2012-11-30       Impact factor: 3.186

View more
  14 in total

1.  Primitive neuroectodermal tumor originating from the lung: A case report.

Authors:  Xin Jin; Jianfeng Cao; Yong Liu; Fang Bian; Qingqing Zhao; Yan Wang; Xu Lv; Yayong Huang
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

2.  The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Cao Dedong; Xu Huilin; He Anbing; Xu Ximing; Ge Wei
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

3.  ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis.

Authors:  Rongzhong Xu; Liubing Lin; Yong Li; Yan Li
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

4.  Herbal Compound Songyou Yin and Moderate Swimming Suppress Growth and Metastasis of Liver Cancer by Enhancing Immune Function.

Authors:  Quan-Bao Zhang; Xiang-Ting Meng; Qing-An Jia; Yang Bu; Zheng-Gang Ren; Bo-Heng Zhang; Zhao-You Tang
Journal:  Integr Cancer Ther       Date:  2015-12-22       Impact factor: 3.279

Review 5.  Recent Advances in Herbal Medicines for Digestive System Malignancies.

Authors:  Jiyao Sheng; Xiaohan Zou; Ziqian Cheng; Yien Xiang; Wei Yang; Yang Lin; Ranji Cui
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

6.  Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells.

Authors:  Ying Xiong; QiuYu Zhao; LiYan Gu; ChunYing Liu; Chun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-16       Impact factor: 2.629

7.  Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial.

Authors:  Xing Zheng; Wenmin Wang; Gefei Wang; Shenghua Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

8.  Management of advanced gastric cancer: An overview of major findings from meta-analysis.

Authors:  Xiaolong Qi; Yanna Liu; Wei Wang; Danxian Cai; Wende Li; Jialiang Hui; Chuan Liu; Yanxia Zhao; Guoxin Li
Journal:  Oncotarget       Date:  2016-11-22

9.  Yangyin Fuzheng Decoction enhances anti-tumor efficacy of cisplatin on lung cancer.

Authors:  Dongmei Wei; Lin Wang; Yuhan Chen; Gang Yin; Mei Jiang; Rui Liu; Hong Chen; Xiyuan Sun
Journal:  J Cancer       Date:  2018-04-12       Impact factor: 4.207

10.  ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis.

Authors:  Hongbo Zhang; Tingting Chen; Lizhu Shan
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.